Cure Today

FDA Approves PD-L1 Test to Guide Keytruda Use in Esophageal and GEJ Cancer

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda. Agilent Technologies Inc. announced that the U.S. Food and ...
Cure Today

FDA Clears PD-L1 Test to Guide Keytruda Use in Ovarian Cancer

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive Keytruda. The U.S. Food and Drug Administration (FDA) has approved PD ...
Nasdaq

Angle PLC Announces Launch of PD-L1 Test to Support Cancer Studies

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
Business Wire

LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO®

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH) a leading global life sciences company, today announced the U.S. availability of the PD-L1 IHC 28-8 pharmDx assay as a complementary diagnostic ...
Business Wire

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR 1 ...